[1]姬　萌,马媛媛,郭醉爽,等.昆仙胶囊与他克莫司治疗特发性膜性肾病疗效比较[J].新乡医学院学报,2021,38(5):472-476.[doi:10.7683/xxyxyxb.2021.05.016]
　JI Meng,MA Yuanyuan,GUO Zuishuang,et al.Comparison of the effects of Kunxian capsule and tacrolimus in the treatment of idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2021,38(5):472-476.[doi:10.7683/xxyxyxb.2021.05.016]
点击复制

昆仙胶囊与他克莫司治疗特发性膜性肾病疗效比较
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年5
页码:
472-476
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Comparison of the effects of Kunxian capsule and tacrolimus in the treatment of idiopathic membranous nephropathy
作者:
姬　萌1; 马媛媛1; 郭醉爽2; 吴茜彤3; 孟园园1; 马东红1; 侯玉龙1; 尚瑞华1; 郭明好1
（1.新乡医学院第一附属医院肾脏病医院，河南　卫辉　453100；2.郑州大学第一附属医院肾内科，河南　郑州　450000；3.新乡市第一人民医院肾内科，河南　新乡　453000）
Author(s):
JI Meng1; MA Yuanyuan1; GUO Zuishuang2; WU Xitong3; MENG Yuanyuan1; MA Donghong1; HOU Yulong1; SHANG Ruihua1; GUO Minghao1
(1.Nephrology Hospital,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,Henan Province,China2.Department of Nephrology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan Province,China3.Department of Nephrology,the First People′s Hospital of Xinxiang City,Xinxiang 453000,Henan Province,China)
关键词:
特发性膜性肾病; 昆仙胶囊; 他克莫司; 糖皮质激素; 疗效
Keywords:
idiopathic membranous nephropathyKunxian capsuletacrolimusglucocorticoidcurative effect
分类号:
R692
DOI:
10.7683/xxyxyxb.2021.05.016
文献标志码:
A
摘要:
目的　比较昆仙胶囊与他克莫司治疗特发性膜性肾病（IMN）的疗效及安全性。方法　选择2019年3月至2020年1月在新乡医学院第一附属医院肾脏病医院行肾活检确诊为IMN的患者60例为研究对象，将患者随机分为昆仙胶囊组和他克莫司组，每组30例。昆仙胶囊组患者给予昆仙胶囊联合糖皮质激素治疗，他克莫司组患者给予他克莫司联合糖皮质激素治疗。记录2组患者治疗前及治疗1、3、6、12个月的24 h尿蛋白定量、血清白蛋白水平，比较2组患者的总有效率、完全缓解率及不良反应。结果　昆仙胶囊组共28例患者完成随访，他克莫司组共30例患者完成随访。治疗1、3、6、12个月时，2组患者的完全缓解率比较差异均无统计学意义（χ2=1.047、0.259、0.074、0.006，P＞0.05）。治疗1个月时，昆仙胶囊组患者的总有效率高于他克莫司组（χ2=5.557，P＜0.05）；治疗3、6、12个月时，2组患者的总有效率比较差异无统计学意义（χ2=1.479、0.265、0.251，P＞0.05）。治疗前，2组患者24 h尿蛋白、血清白蛋白水平比较差异无统计学意义（P＞0.05）。昆仙胶囊组患者治疗1、3、6、12个月时24 h尿蛋白水平均低于治疗前 (P＜0.05)；治疗12个月时，昆仙胶囊组患者24 h尿蛋白水平低于治疗1个月时 (P＜0.05)。他克莫司组患者治疗6、12个月时24 h尿蛋白水平低于治疗前及治疗1、3个月时 (P＜0.05)。治疗1、3个月时，他克莫司组患者24 h尿蛋白水平高于昆仙胶囊组(P＜0.05)；治疗6、12个月时，2组患者的24 h尿蛋白水平比较差异无统计学意义（P＞0.05）。治疗3、6、12个月时，昆仙胶囊组患者的血清白蛋白水平均高于治疗前及治疗1个月时 (P＜0.05)；治疗6、12个月时，昆仙胶囊组患者血清白蛋白水平均高于治疗3个月时(P＜0.05)。治疗1、3、6、12个月时，他克莫司组患者的血清白蛋白水平均高于治疗前(P＜0.05)；治疗6、12个月时，他克莫司组患者血清白蛋白水平均高于治疗1、3个月时 (P＜0.05）。治疗1、3个月时，他克莫司组患者血清白蛋白水平高于昆仙胶囊组(P＜0.05)；治疗6、12个月时，2组患者的血清白蛋白水平比较差异无统计学意义（P＞0.05）。昆仙胶囊组患者不良反应发生率为21.4%(6/28)，他克莫司组患者不良反应发生率为46.7%(14/30)；昆仙胶囊组患者不良反应发生率低于他克莫司组(χ2=4.083，P＜0.05)。结论　昆仙胶囊联合糖皮质激素治疗IMN的疗效与他克莫司联合糖皮质激素方案相当，且起效更快、安全性好，是治疗IMN的有效方案之一。
Abstract:
Objective　To compare the efficacy and safety of Kunxian capsule and tacrolimus in the treatment of idiopathic membranous nephropathy（IMN）.Methods　A total of 60 patients who were diagnosed as IMN by renal biopsy at the Nephrology Hospital of the First Affiliated Hospital of Xinxiang Medical University from March 2019 to January 2020 were selected as study subjects and they were randomly divided into Kunxian capsule group and tacrolimus group,with 30 cases in each group.Patients in the Kunxian capsule group were treated with Kunxian capsule combined with glucocorticoids,and the patients in the tacrolimus group were treated with tacrolimus combined with glucocorticoids.The 24-hour urine protein quantification and serum albumin level of patients in the two groups were recorded before treatment and 1,3,6,12 months of treatment;the total effective rate,complete remission rate and adverse reactions of the patients between the two groups were compared.Results　A total of 28 patients in the Kunxian capsule group completed the follow-up,and a total of 30 patients in the tacrolimus group completed the follow-up.There was no significant difference in the complete remission rate of patients between the two groups at 1,3,6 and 12 months of treatment (χ2=1.047,0.259,0.074,0.006;P>0.05).At 1 month of treatment,the total effective rate of patients in the Kunxian capsule group was significantly higher than that in the tacrolimus group (χ2=5.557,P<0.05);at 3,6 and 12 months of treatment,there was no significant difference in the total effective rate of patients between the two groups (χ2=1.479,0.265,0.251;P>0.05).Before treatment,there was no significant difference in the levels of 24-hour urine protein and serum albumin levels of patients between the two groups (P>0.05).The 24-hour urine protein level of patients in the Kunxian capsule group at 1,3,6,and 12 months of treatment was lower than that before treatment (P<0.05);the 24-hour urine protein level of patients in the Kunxian capsule group at 12 months of treatment was lower than that at 1 month of treatment (P<0.05).The 24-hour urine protein level of patients in the tacrolimus group at 6 and 12 months of treatment was significantly lower than that before treatment at 1 and 3 months of treatment (P<0.05).At 1 and 3 months of treatment,the 24-hour urine protein level of patients in the tacrolimus group was significantly higher than that in the Kunxian capsule group (P<0.05);at 6 and 12 months of treatment,there was no significant difference in the 24-hour urine protein level between the two groups (P>0.05).At 3,6,and 12 months of treatment,the serum albumin level of patients in Kunxian capsule group was significantly higher than that before treatment and at 1 month of treatment (P<0.05).At 6 and 12 months of treatment,the serum albumin level of patients in the Kunxian capsule group was significantly higher than that at 3 months of treatment (P<0.05).The serum albumin level of patients in the tacrolimus group at 1,3,6,and 12 months of treatment was significantly higher than before treatment (P<0.05);the serum albumin level of patients in the tacrolimus group at 6 and 12 months of treatment was significantly higher than that at 1 and 3 months of treatment (P<0.05).At 1 and 3 months of treatment,the serum albumin level of patients in the tacrolimus group was significantly higher than that in the Kunxian capsule group (P<0.05);at 6 and 12 months of treatment,there was no significant difference in the serum albumin level of patients between the two groups (P>0.05).The incidence rate of adverse reactions of patients in the Kunxian capsule group was 21.4% (6/28),and the incidence rate of adverse reactions of patients in the tacrolimus group was 46.7% (14/30);the incidence rate of adverse reactions of patients in the Kunxian capsule group was significantly lower than that in the tacrolimus group (χ2=4.083,P<0.05).Conclusion　The efficacy of Kunxian capsule combined with glucocorticoid in the treatment of IMN is equivalent to the tacrolimus combined glucocorticoid regimen,with faster onset and good safety,and it is one of the effective regimens for the treatment of IMN.

参考文献/References:

［1］　SETHI S,DEBIEC H,MADDEN B,et al.Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy［J］.Kidney Int,2020,97(1):163-174.
［2］　PRINTZA N,GEORELI I,STABOULI S et al.Response to:pharmacological treatment of primary membranous nephropathy in 2016［J］.Expert Rev Clin Pharmacol,2018,11(5):459-461.
［3］　ANGIOI A,LEPORI N,LPEZ A C,et al.Treatment of primary membranous nephropathy:where are we now［J］.J Nephrol,2018,31(4):489-502.
［4］　FOUAD M A,MAHEDY A W,MANSOUR A E,et al.Anti-PLA2R and anti-THSD7A as diagnostic serological markers of idiopathic membranous nephropathy:a single centre study［J］.Egypt J Immunol,2020,27(2):1-9.
［5］　王润秀,曹春瑜,汤显湖.雷公藤多甙和环磷酰胺治疗膜性肾病的效果对比［J］.实用医学杂志,2016,32(10):1726-1727.
［6］　孙铁忠，何晓芳．雷公藤多甙与环磷酰胺分别联合泼尼松治疗特发性膜性肾病疗效比较［J］．武警后勤学院学报(医学版)，2018，33(9):e74．
［7］　陆艳.昆仙胶囊治疗类风湿关节炎患者的疗效分析［J］.中国药物经学,2018,13(8):78-80.
［8］　刘艳梅,雷易萌,张贝,等.昆仙胶囊治疗类风湿关节炎的临床研究［J］.解剖科学进展,2019,25(1):17-20.
［9］　李陶冉,史丽璞.昆仙胶囊联合甲氨蝶呤对类风湿关节炎患者的疗效［J］.深圳中西医结合杂志,2018,28(24):28-29.
［10］　彭杰,冯志瑀,苏保林.昆仙胶囊联合泼尼松对慢性肾炎患者24 h尿蛋白定量及肾功能的影响［J］.世界中西医结合杂志,2020,15(7):1273-1276.
［11］　薛丕良，牛雯颖,李丽琦，等.雷公藤多苷联合小剂量激素治疗特发性膜性肾病的前瞻性对照研究［J］.世界中医药，2019，14（3）:666-669.
［12］　COUSER W G.Primary membranous nephropathy［J］.Clin J Am Soc Nephrol,2017,12(6):983-997.
［13］　LIU Y P,ZHENG S S,MA C Q,et al.Meta-analysis of the diagnostic efficiency of THSD7A-AB for the diagnosis of idiopathic membranous nephropathy［J］.Glob Chall,2020,4（11）:1900099.
［14］　SETHI S,MADDEN B J,DEBIEC H,et al.Exostosin 1/Exostosin 2-associated membranous nephropathy［J］.J Am Soc Nephrol,2019,30(6):1123-1136.
［15］　SETHI S,DEBIEC H,MADDEN B,et al.Neural epidermal growth factor-like 1 protein(NELL-1)associated membranous nephropathy［J］.Kidney Int,2020,97(1):163-174.
［16］　张菊.昆仙胶囊治疗肾病综合征疗效及对患者血清IFN-γ和IL-21水平的影响［J］.陕西医学杂志,2020,49(3):345-348.
［17］　黎明阳.昆仙胶囊治疗115例慢性肾脏病的临床疗效观察［D］.沈阳:中国医科大学,2018.
［18］　FRANCAVILLA A,STARZL T E,BARONE M,et al.Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK506［J］.Hepatology,1991,14(1):140-143.

相似文献/References:

[1]马媛媛,姬　萌,郭醉爽,等.昆仙胶囊治疗原发性IgA肾病疗效观察[J].新乡医学院学报,2021,38(10):961.[doi:10.7683/xxyxyxb.2021.10.013]
　MA Yuanyuan,JI Meng,GUO Zuishuang,et al.Effect of Kunxian capsule in the treatment of primary IgA nephropathy[J].Journal of Xinxiang Medical University,2021,38(5):961.[doi:10.7683/xxyxyxb.2021.10.013]
[2]朱佳佳,马东红,刘　云,等.特发性膜性肾病患者足突宽度与尿蛋白量和他克莫司治疗反应的关系[J].新乡医学院学报,2017,34(5):381.[doi:10.7683/xxyxyxb.2017.05.009]
　ZHU Jia-jia,MA Dong-hong,LIU Yun,et al.Relationship between the foot process width，urinary protein and the patient′s response to tacrolimus in patients with idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2017,34(5):381.[doi:10.7683/xxyxyxb.2017.05.009]
[3]阎　磊,范晓光,高素华,等.肾组织M-型磷脂酶A2受体抗原阳性的特发性膜性肾病患者临床特征分析[J].新乡医学院学报,2017,34(8):700.[doi:10.7683/xxyxyxb.2017.08.010]
　YAN Lei,FAN Xiao-guang,GAO Su-hua,et al.Clinical features of patients with kidney tissue M-type phospholipase A2 receptor antigen positive idiopathic membranous nephropathy[J].Journal of Xinxiang Medical University,2017,34(5):700.[doi:10.7683/xxyxyxb.2017.08.010]

更新日期/Last Update: 2021-05-05